The clinical pharmacology of amoxicillin and clavulanic acid

Pediatric Infectious Disease Journal

Volumn 17, Issue 10, 1998, Pages 957-962

  Reed, Michael D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amoxicillin; Amoxicillin clavulanate; Augmentin ; Clavulanic acid

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFPODOXIME; CEFPROZIL; CEFTIBUTEN; CEFUROXIME; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN ESTOLATE; ERYTHROMYCIN ETHYLSUCCINATE; PENICILLIN V; SULFAFURAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; HUMANS; OTITIS MEDIA; PENICILLINS;

EID: 0031761983     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199810000-00040     Document Type: Article

References (44)

1. Bonafede ME, Blumer JL. Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children. Adv Pediatr Infect Dis 1997;12:71-108.
2. Reed MD, Blumer JL. Amoxicillin-clavulanate: rational pharmacology meets clinical infectious disease [Editorial]. Clin Pharm 1984;3:653-4.
3. Bush LM, Calmon J, Johnson CC. Newer penicillins and beta-lactamase inhibitors. Infect Dis Clin North Am 1995;9:653-86.
4. Sensakovic JW, Smith LG. Beta-lactamase inhibitor combinations. Med Clin North Am 1995;79:695-704.
5. Rolinson GN, Stevens S. Microbiological studies on a new broad-spectrum penicillin "Penbritin." Br Med J 1961;2:191-6.
6. Gurwith MJ, Rabin HR, Love K. Co-operative Antibiotic Diarrhea Study Group. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a co-operative study. J Infect Dis 1977; 135(Suppl):104-10.
7. Lusk RH, Fekety FR Jr, Silva J Jr, et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis 1977;135(Suppl):111-9.
8. Neu HC. Diagnosis and treatment: drugs five years later: amoxicillin. Ann Intern Med 1979;90:356-60.
9. Table A-11-1: Pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1715-6.
10. Spyker DA, Rugloski RJ, Vann RL, O'Brien WM. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral and intramuscular administration. Antimicrob Agents Chemother 1977;11:132-41.
11. Arancibia A, Guttman J, Gonzalez G, Gonzalez C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 1980;17:199-202.
12. Ginsburg CM, McCracken GH Jr, Thomas ML, Clahsen J. Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children. Pediatrics 1979;64:627-31.
13. Schaad UB, Casey PA, Ravenscroft T. Pharmacokinetics of a syrup formulation of amoxicillin-potassium clavulanate in children. J Antimicrob Chemother 1986;17:341-5.
14. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanic acid. Pediatr Infect Dis J 1996;15(Suppl):949-54.
15. Neu HC. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med 1985;79(Suppl 5B):2-12.
16. Mollering RC Jr. Meeting the challenges of beta-lactamases. J Antimicrob Chemother 1993; 31(Suppl):1-8.
17. Severin A, Severina E, Tomasz A. Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanic acid. Antimicrob Agents Chemother 1997;41:504-10.
18. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990;39:264-307.
19. Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother 1978;14:539-43.
20. Staniforth DH, Clarke HL, Horton R, Jackson D, Lau D. Augmentin bioavailability following cimetidine, aluminum hydroxide and milk. Int J Clin Pharmacol Ther Toxicol 1985;23:154-7.
21. Kucers A, Bennett NMcK. Ampicillin-like penicillins. In: Kucers A, Bennett NMcK, eds. The use of antibiotics: a comprehensive review with clinical emphasis. 4th ed. Philadelphia: Lippincott, 1987:181-2.
22. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
23. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995l14:S93-101.
24. Shyu WC, Haddad J, Reilly J, et al. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994;38:2210-12.
25. Krause PJ, Ownes NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic otitis media. J Infect Dis 1982;145:815-21.
26. Klimek JJ, Nightingale C, Lehmann WB, Quintiliani R. Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. J Infect Dis 1977;135:999-1002.
27. Eden T, Anari M, Ernstson S, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear fluid in secretory otitis media. Scand J Infect Dis 1983;39(Suppl):49-52.
28. Harrison CJ, Chartrand SA, Rodriguez W, et al. Middle ear fluid (MEF) concentrations of cefixime (Cfxm) in acute otitis media (AOM) and otitis media with effusion (OME). Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
29. Kafetzis DA, Carabinos C, Bairamis T, Apostolopoulos N. Diffusion of four oral cephalosporins into the middle ear exudate (MEE) of children suffering from acute otitis media (AOM). Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October, 1993.
30. Haddad J, Isaacson G, Respler DS, et al. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil. Pediatr Infect Dis J 1991;10:294-8.
31. Kusmiesz H, Shelton S, Brown O, Manning S, Nelson JD. Loracarbef concentrations in middle ear fluid. Antimicrob Agents Chemother 1990;34:2030-1.
32. Nelson CT, Mason EO, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994;13:585-9.
33. Guay DRP, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993;12:S106-11.
34. Bakken JS, Bruun JN, Gaustad P, Tasker TC. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother 1986;30:481-4.
35. Syrogiannopoulos GA, Al-Sabbagh A, Olsen KD, McCracken GH Jr. Pharmacokinetics and bacteriological efficacy of ticarcillin-clavulanic acid (Timentin) in experimental Escherichia coli K-1 and Haemophilus influenzae type b meningitis. Antimicrob Agents Chemother 1987;31:1296-300.
36. Mizen L, Woodnutt G, Kernutt I, Catherall EJ. Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis. Antimicrob Agents Chemother 1989;33:693-9.
37. Adam D, Visser ID, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone or in combination. Antimicrob Agents Chemother 1982;22:353-7.
38. Croydon P. A worldwide survey of clinical experience with Augmentin. J Drug Dev 1989;2(Suppl):67-9.
39. Neu HC, Wilson APR, Gruneberg RN. Amoxicillin/clavulanic acid: a review of its efficacy in over 38 500 patients from 1979 to 1992. J Chemother 1993;5:67-93.
40. Reed MD, Blumer JL. Azithromycin: a critical review of the first azalide antibiotic and its role in pediatric practice. Pediatr Infect Dis J 1997;16:1069-83.
41. Caron F, Ducrotte P, Lerebours E, Colin R, Humbert G, Denis P. Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings. Antimicrob Agents Chemother 1991;35:1085-8.
42. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997;16:463-70.
43. Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997;16:710-1.
44. Bottenfield GW, Burch DJ, Hedrick JA, Schaten R, Rowinski CA, Davies JT. Safety and tolerability of a new formulation (90 mg/kg/day divided q 12) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998;17(Suppl):963-8.